Tempest Therapeutics is a San Francisco-based biotechnology startup founded in 2011. The company is focused on pioneering the future of cancer treatment through innovative small molecule therapeutics that enhance anti-tumor immunity. Tempest Therapeutics has garnered attention due to its balanced and extensive pipeline, featuring first-in-class and best-in-class small molecule therapeutics targeting distinct pathways crucial for an effective anti-tumor response. Their last investment of $15.00M in post-IPO equity came on 27 April 2022, with backing from Versant Ventures and EcoR1 Capital. Specializing in the biotechnology and health care industries, Tempest Therapeutics continues to be a key player in the development of novel cancer treatment solutions.
Tempest Therapeutics
Pioneering the future of cancer treatment with innovative small molecule therapeutics that enhance anti-tumor immunity.
General Information
BounceWatch is an independent company data service, not affiliated with Tempest Therapeutics. To contact Tempest Therapeutics, visit tempesttx.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Tempest Therapeutics compare?
A PDF of Tempest Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Tempest Therapeutics soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
About Tempest Therapeutics
Business keywords: Cancer Treatment, Small Molecule Therapeutics, Anti-Tumor Immunity, Immunotherapy, Drug Development, Biopharmaceuticals, San Francisco, Immuno-Oncology, Pipeline Development
Funding Rounds & Investors (3)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post IPO Equity | $15.00M | 2 |
|
27 Apr 2022 |
| Series B | $70.00M | 6 |
|
28 Mar 2018 |
| Venture Round | $5.00M | - |
|
05 Oct 2011 |
Tempest Therapeutics Alternatives & Competitors
View All Alternatives
Discovering innovative small molecule therapeutics for the treatment of cancer
Pioneering novel therapies with promising small molecule kinase inhibitors for a brighter future in...
Synthetic lethality precision medicine oncology company pursuing– an emerging class of precision med...
FAQ About Tempest Therapeutics
Source: BounceWatch company record for Tempest Therapeutics, https://bouncewatch.com/company/tempest-therapeutics, updated 9 November 2024. When citing, please name BounceWatch and link this page.
